Sponsors (3)
Directs FDA to study preterm infant formula safety and law, recommend whether manufacturers need premarket approval, and temporarily preempts differing State/local rules for two years.
The bill aims to improve safety oversight and nationwide availability of preterm infant formula through temporary federal uniformity and an FDA premarket pathway, but it does so at the cost of temporarily limiting state regulatory authority and narrowing or delaying consumer legal remedies against manufacturers.
Parents and caregivers of preterm or low‑birth‑weight infants will face stronger federal premarket oversight if FDA pursues and implements premarket approval for preterm infant formula manufacturers, which could reduce safety risks for these infants.
Manufacturers and parents benefit from two years of federal uniformity preventing a patchwork of state rules, reducing compliance complexity for producers and helping keep preterm formulas available across all states.
Congress, state health systems, and hospitals will receive a timely, evidence‑based report within two years on availability, safety, and legal gaps for preterm formulas to inform future policymaking.
State governments and parents lose the ability for two years to adopt or enforce stricter safety or labeling rules for preterm formulas, which could delay stronger local protections where states would otherwise act.
Parents and consumers facing harm may find it harder to obtain remedies because the bill raises the burden to prove willful misconduct by manufacturers and allows manufacturers to move state suits to federal court or seek dismissal, potentially delaying or limiting legal recourse.
Based on analysis of 2 sections of legislative text.
Official title: To ensure national uniformity with respect to certain requirements relating to preterm infant formula, and for other purposes.
Introduced March 24, 2025 by Diana Harshbarger · Last progress March 24, 2025
Directs the FDA (via the HHS Secretary) to study availability, safety, and the legal landscape for preterm infant formula and to recommend whether premarket approval should be required for its manufacturers, with a report to Congress due within two years. For two years after enactment, the bill temporarily blocks State or local rules that differ from specified Federal requirements for preterm infant formula, while preserving State civil/criminal claims for willful misconduct (with a clear-and-convincing burden and limited removal rules).